Joe Cobb, Anshul Gupte, Metrics Contract Services 10.11.16
With 32 years of pharmaceutical industry experience between us, we have worked on hundreds of early-phase, solid-oral dosage development projects involving many different kinds of clients. The number of projects from virtual pharmaceutical companies continues to increase, however, these companies face special challenges.
Today, the typical virtual pharma company possesses one active pharmaceutical ingredient (API) it acquired from a Big Pharma company after the API failed to advance within an expected therapeutic area. Sometimes, however, that API still holds promise for another therapeutic area. With venture capital funding and a small staff, a virtual pharma company can start exploring that option.
Through collaborative partnerships with contract development and manufacturing organziations (CDMOs), virtual pharma can, ultimately, position their products for greater success in clinical studies. The following are tips for how a virtual pharma company can maximize its potential for success when partnering with a CDMO.
Conduct an internal needs assessment
Virtual pharma companies tend
Today, the typical virtual pharma company possesses one active pharmaceutical ingredient (API) it acquired from a Big Pharma company after the API failed to advance within an expected therapeutic area. Sometimes, however, that API still holds promise for another therapeutic area. With venture capital funding and a small staff, a virtual pharma company can start exploring that option.
Through collaborative partnerships with contract development and manufacturing organziations (CDMOs), virtual pharma can, ultimately, position their products for greater success in clinical studies. The following are tips for how a virtual pharma company can maximize its potential for success when partnering with a CDMO.
Conduct an internal needs assessment
Virtual pharma companies tend
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
